DC-SIGNR基因多态性与丙型肝炎病毒载量的相关性研究

目的了鹪丙型肝炎患者DC-SIGN／DC-SIGNR基因颈区重复序列的遗传多态性分布，探讨DC-SIGNR基因多态性与丙型肝炎病毒（HCV）载量的关系。方法采用PCR结合DNA测序对300例丙型肝炎患者DC—SIGNR重复序列多态性进行基因分型和测序分析；同时检测了患者的HCV病毒载量。结果该研究发现携带7等位基因（中等的）的患者、其HCV病毒载量水平低于携带9等位基因（较长的）的患者（P〈0.05），此外7／7基因型的患者组其HCV病毒载量水平低于9／7基因型的患者组，两组的差异有统计学意义（P〈0．05）、提示HCV病毒更易与携带较长DC—SINGR等位基因的患者结合。结论DC-SIGNR遗传多态性可能与HCV病毒在个体内的复制有关。     

宫腹腔镜联合应用诊治输卵管性不孕的临床研究

目的:探讨宫腔镜、腹腔镜联合诊治输卵管阻塞性不孕的效果。方法:对诊断为不孕症的病人,首先进行输卵管通液术,对于通液结果为输卵管不通者,应用76%的泛影葡胺行子宫、输卵管造影。对诊断为双侧输卵管阻塞者则宫腔镜与腹腔镜联合应用,宫腔镜下观察宫腔内、输卵管、子宫口是否存在病变,做选择性输卵管插管通液术,腹腔镜直视下观察输卵管阻塞度及阻塞部位,并做相应手术。结果:双侧通畅15例,一侧通对侧阻塞9例,一侧通而不畅对侧通畅6例,双侧阻塞2例。均较单用宫腔插管通液效果好。结论:宫、腹腔镜联合能充分利用二者的优点,相互补充,明确输卵管阻塞的部位和程度,对输卵管复通有一定临床价值。     

5''-磷酸胞苷体外抗氧化作用的研究

近年来的研究表明,5'-核苷酸具有提高免疫力、促生长、抗氧化、促进机体损伤修复、减少细胞凋亡、减轻炎性反应等功能[1-4].但关于5'-核苷酸的抗氧化作用机制尚无系统研究.本研究分析体外条件下5'-磷酸胞苷(5'-CMP)的清除活性氧能力及其对氧化损伤小鼠脾细胞的修复作用,旨在阐明其可能的作用机制.     

毫针浅刺法治疗椎基底动脉供血不足的疗效观察

[目的]探讨毫针浅刺法针灸治疗椎基底动脉供血不足症(VBI)的临床疗效。[方法]将40例患者随机分为观察组和对照组各20例,观察组采用毫针浅刺法治疗,对照组采用常规针刺法治疗,两组均每日治疗1次,10天为1个疗程,均治疗两个疗程后判断疗效。[结果]观察组痊愈17例,显效2例,无效1例,总有效率为95.0%;对照组痊愈9例,显效7例,无效4例,总有效率为80.0%。观察组疗效明显优于对照组(P<0.05)。[结论]浅刺法针灸治疗椎基底动脉供血不足症(VBI)疗效显著。     

复肝解毒汤治疗慢性乙型肝炎36例

为观察自拟复肝解毒汤（主药;虎杖、白花蛇舌草、田基黄、广郁金、川楝子、白芍药、柴胡、生麦芽、五味子、砂仁）的疗效,将72例慢性乙型肝炎患者,随机分为两组,治疗组（36例）肝炎灵加服复肝解毒汤,对照组（36例）用肝炎灵加服乙肝清热解毒冲剂。观察治疗中（4周）、后（12周）症状体征及实验室指标的变化。结果：两组患者症状体征的改善情况相似;治疗组ALT、AST、TBiL在第4周已有明显降低,而对照组在12周明显降低;肝功能的复常率和HBV－DNA、HbeAg的转阴率治疗组优于对照组,但无统计学意义。提示复肝解毒汤能缩短慢性乙型肝炎的疗程。     

Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer

OBJECTIVES: To determine the efficacy of a three-fold reduced dose (RD, 27 mg) of intravesical bacille Calmette-Guérin (BCG) against the standard dose (81 mg) in patients with superficial bladder cancer, assessing recurrence, progression and differences in toxicity. PATIENTS AND METHODS: Five hundred patients with superficial bladder cancer (Ta, T1, Tis) were enrolled and randomly assigned to be treated after transurethral resection of all visible lesions with intravesical BCG Connaught strain (weekly x six and thereafter fortnightly x six) either with the standard or RD instillation. RESULTS: All but one of the 500 patients were evaluable for efficacy and toxicity (252 in the standard arm and 247 in the RD arm). The median follow-up was 69 months (maximum 104); 71 (28%) patients in the standard arm and 76 (31%) in the RD arm developed recurrences; the median time to recurrence has not yet been attained, but at 5 years the mean (sd) percentage of recurrence-free patients was 70.5 (3.12) and 70.4 (3.1) for the standard and RD arms, respectively. In patients presenting with multifocal tumours, the standard dose was more effective against recurrences than the RD (P=0.0151). In those with G3 and high-risk tumours overall, the superiority of the standard dose was marginal (P=0.060 and P=0.082). Twenty-nine (11.5%) tumours in the standard arm and 33 (13.3%) in the RD arm progressed to invasive disease; the median time to progression has not yet been attained, but the percentage of progression-free patients at 5 years was 88.8 (2.23) and 86.9 (2.31) for the standard and RD arms, respectively. The standard dose was more effective than the RD against progression only in patients with multifocal disease (P=0.048). Twelve (4.8%) cystectomies were performed in the standard and 15 (6.1%) in the RD arm. Currently, 106 (21.2%) patients have died, but only 38 (7.6%) from bladder cancer, i.e. 20 (7.9%) in the standard and 18 (7.5%) in RD arm. Overall the disease-specific death rate was lower for those patients who completed the scheduled treatment. The cause-specific survival at 5 years did not differ between the arms (P=0.76) but there was a trend toward better cause-specific survival for patients with multifocal tumours in the standard arm. Toxicity differed between the arms, significantly more patients having no toxicity in the RD arm, and fewer having delayed instillations or withdrawing. However, severe systemic toxicity occurred even in patients treated with the RD, in a similar proportion to those receiving the standard dose. CONCLUSION: Overall, the RD gave similar results for recurrence and progression but with significantly less toxicity. However, patients with multifocal tumours fared better with the standard dose and there was a trend towards better recurrence rates in patients with high-risk tumours. We recommend continuing to use the standard dose for high-risk tumours, while we consider the reduced dose safe and effective for intermediate-risk lesions and for maintenance schedules.     

HIV-Ⅰ CN54株gagprotease基因嵌合脊髓灰质炎病毒cDNA质粒的构建和表达研究

目的 构建HIV-1 CN54株gagprotease基因嵌合脊髓灰质炎病毒cDNA的表达质粒，并鉴定、检测基因及其表达。方法 用PCR技术获得人免疫缺陷病毒CN54株的gagprotease基因，并使其两端带上合适的酶切住点，将其定向插入到包含脊髓灰质炎病毒cDNA的表达质粒pSVA14中，替代其部分结构基因，构建HIV基因嵌合缺陷性脊髓灰质炎病毒基因组的表达质粒。经筛选、鉴定后用脂质体转染技术将新构建的质粒转入Hela细胞内，用Western Blot方法检测目的基因在Hela细胞内的表达。结果 PCR技术扩增所得的人免疫缺陷病毒CN54株gagprotease基因经琼脂糖凝胶电泳、DNA测序证实成功获得，未引入突变碱基，筛选、鉴定证明gagprotease基因被正确定向插入到脊髓灰质炎病毒的cDNA序列之中，Western Blot检测到gagpro-tcase基因正确表达了相关蛋白。结论 成功构建了表达人免疫缺陷病毒CN54株gagprotease基因的缺陷性脊髓灰质炎病毒基因组嵌合质粒，为利用脊髓灰质炎病毒作人免疫缺陷病毒基因的表达载体奠定了基础，此研究对开发以脊髓灰质炎病毒为艾滋病的疫苗载体有重要意义。     

自我效能感与晕船症状的相关研究

目的 探讨自我效能感与晕船症状的相关，以期寻找影响晕船的心理因素。方法 对某院校参加海上实习的123名医疗本科学员用一般自我效能感量表、晕船自我效能感量表于出海作业前进行施测，用晕船症状评分量表于出海作业返回后进行评估。结果 晕船自我效能感与晕船症状显著负相关（r=-0．470，P〈0．01），而一般自我效能感量表与晕船症状的相关无统计学意义（r=-0．102，P〉0．05）。结论 晕船自我效能感可能为个体发生晕船的心理影响因素之一。     

羟基磷灰石/聚合物复合材料的研究进展

该文对羟基磷灰石与天然生物材料、人工合成的医用可生物降解高分子材料以及医用非降解高分子材料的研究应用与进展进行了总结.并对羟基磷灰石/聚合物复合材料的发展趋势进行了探讨.